ZOFRAN
LOE ApproachingNDAORALTABLETPriority Review
Approved
Dec 1992
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
3/8 — Basic
Priority Review
ZOFRAN by Novartis. Approved for nausea and vomiting, chemotherapy-induced nausea and vomiting. First approved in 1992.
Drug data last refreshed 20h ago
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Clinical Trials (2)
Casopitant (Oral) And ZOFRAN To Prevent Postoperative Nausea And Vomiting In Women
Started Mar 2006
482 enrolled
Nausea and Vomiting, Postoperative
Casopitant And ZOFRAN To Prevent Post Operative Nausea And Vomiting In Women
Started Mar 2006
515 enrolled
Nausea and Vomiting, PostoperativePostoperative Nausea and Vomiting
Worked on ZOFRAN at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.